Metastatic melanoma has long been one of the most challenging malignancies to treat, largely due to its notorious resistance to traditional chemotherapy and radiation. For patients who do not respond to initial immunotherapy, the clinical options have historically been bleak. However, the emergence of tumor-infiltrating lymphocyte (TIL) therapy is changing the prognosis for this difficult-to-treat population.
Muhammad Umair Mushtaq, MD, associate professor of medicine in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, delved into the unique mechanics of TIL therapy as a distinct modality of immunotherapy. Unlike historical treatments that offered success to only a small fraction of patients, TIL therapy has demonstrated the ability to overcome treatment resistance and provide a lifeline for those with advanced disease.
Mushtaq highlighted the significant clinical impact of TILs, including:
- Overcoming Chemoresistance: Why cellular therapy succeeds where traditional agents fail.
- High Response Rates: Achieving deep, durable responses in one-third of patients.
- Long-Term Remission: Sustained clinical success lasting beyond 4 years in approximately 10% of cases.
Transcript:
They are hard to treat because, historically, chemotherapy or chemoradiotherapy has not been effective in melanoma. Melanoma is one of the cancers that’s very resistant to chemotherapeutic agents. Once it is metastatic, there have been very limited options. Historically, there have been, as I said previously, TIL trials in [certain therapies] and high-dose IL-2. There are immunotherapeutic approaches, and those approaches give responses in 5% to 10% of patients. TIL therapy in these patients…it’s a different modality of immunotherapy. That’s why it works in these patients. It does give deep, durable responses in one-third of patients, and there are sustained remissions beyond 4 years in up to 10% of patients.
